Showing 44 Focus
Sort by:


  • Fraqtal • Psychedelic Survey • Aurelius Data • Blossom • Maya • Psychedelic Invest • Psychedelic Support • Quantified Citizen • Report on Psychedelics • Tune In Psychedelics • PsyIndex • Introspect • Opportune • Total Brain • Viridia Life Science • Neuly • Prohibition Partners • Mindstrong • PatientSafe Solutions • Speak Ai • Apollo Neuro • Sana Health • Pharmather • ilumivu • Reconscious Medical • Puff Digital • MyDelica • Emyria • Mindseye • Apotheca • Enter Here • Heally • Psynautics • Albert Labs • Cognistx • Psychable • Cydelic • Nue Life
  • Clinical Data Manager


  • Green Light Medicines • Diamond Therapeutics • MAPS Public Benefit Corporation • Center for the Neuroscience of Psychedelics • Awakn Life Sciences, Inc. • Canada Research Chemicals • Beckley Psytech • MagicMed Industries • IntelGenx • Tryp Therapeutics • CLOV Biopharma Corp • Lundbeck • Mimosa Therapeutics • Magical Brands • M2BIO • Psilera Biosciences • Bionomics • Physiogenix • BioPharm • Dalriada • Jaguar Health • Pharmather • Noetic Foundry • Empath Bio • Pilz BioScience • Allied Corp • Journey Colab • Mera Life Sciences • Olson Lab • XPhyto • ProPharma Group • Optimi Health • AIkido Pharma • Psyence • HealthTech Connex • Terran Biosciences • Nirvana Life Sciences • Algernon Pharmaceuticals • Conscious Mind • Ninnion • AMRI • GoodCap • Terasaki Institute • Syreon Research Institute • MYND Life Sciences Inc. • The Psynergia Alliance • GH Research • Lattice Biologics • Halucenex • CURE Pharmaceutical • Psy Therapeutics • PsiloTec • Filament • Wesana • Reset Pharma • Cannabics Pharmaceuticals • Mycrodose Therapeutics • Cubed3 Biotech • Clarify Pharma PLC • Wonder Sciences • Lennham Pharmaceuticals • PharmAla Biotech • MAPS • Woven Science • BetterLife Pharma Inc. • HMNC Brain Health • Aphrodite Health • Ketamine One • Goodness Growth • Clearmind • Eastra Health • Kaiyon Biotech • Psylo • MindBio Therapeutics


  • CB Therapeutics • Entheon • Alien Insect • Psilohuasca • CaaMTech • Viridia Life Science • DMTx • Legit Research Chemical Vendors USA • XPhyto • Algernon Pharmaceuticals • GH Research • The Sentinel • Mr. Psychedelic Law • Limina Foundation • Society for Psychedelic Outreach Reform and Education (SPORE) • Small Pharma • Psilera Biosciences • MagicMed Industries • Mindset Pharma • ATAI Life Sciences
  • Human psychopharmacology of N, N-dimethyltryptamine • The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator • N, N-dimethyltryptamine: an endogenous hallucinogen • A dimethyltryptamine-forming enzyme in human blood • The psychedelic model of schizophrenia: the case of N, N-dimethyltryptamine • Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids • Dose-response study of N, N-dimethyltryptamine in humans: I. Neuroendocrine, autonomic, and cardiovascular effects • Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine • Dose-response study of N, N-dimethyltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale • Effects of 5-methoxy-N, N-dimethyltryptamine on central monoamine neurons • Hydroxylation and N-demethylation of N, N-dimethyltryptamine • Behavioral effects of 5-methoxy-N: N-dimethyltryptamine, other tryptamines, and LSD • A Fatal Intoxication Following the Ingestion of 5-Methoxy-N,N-Dimethyltryptamine in an Ayahuasca Preparation • When the endogenous hallucinogenic trace amine N, N-dimethyltryptamine meets the sigma-1 receptor • Quantitation of N,N-Dimethyltryptamine and Harmala Alkaloids in Human Plasma after Oral Dosing with Ayahuasca • Dimethyltryptamine experiments with psychotics • Agonist properties of N, N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors • Neuropharmacology of N, N-dimethyltryptamine • DISCARNATE ENTITIES AND DIMETHYLTRYPTAMINE (DMT): PSYCHOPHARMACOLOGY, PHENOMENOLOGY AND ONTOLOGY. • Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies • Differential tolerance to biological and subjective effects of four closely spaced doses of N, N-dimethyltryptamine in humans • Metabolism of the hallucinogen N, N-dimethyltryptamine in rat brain homogenates • In vivo metabolism of 5-methoxy-N, N-dimethyltryptamine and N, N-dimethyltryptamine in the rat • Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N, N-dimethyltryptamine in the rat • Psychedelic 5-methoxy-N, N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions • Dimethyltryptamine levels in blood of schizophrenic patients and control subjects • Programmed communication during experiences with DMT (dimethyltryptamine) • Studies on the mechanism of action of monoamine oxidase: metabolism of N, N-dimethyltryptamine and N, N-dimethyltryptamine-N-oxide • Differential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors • Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter • t-Amine oxide rearrangements. N, N-Dimethyltryptamine oxide • Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N, N-dimethyltryptamine in rats treated with a monoamine … • Blood and urine levels of N, N-dimethyltryptamine following administration of psychoactive dosages to human subjects • Unmasking of a neonatal somatovesical reflex in adult cats by the serotonin autoreceptor agonist 5-methoxy-N, N-dimethyltryptamine • Effects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression • Psychedelic N, N-dimethyltryptamine and 5-methoxy-N, N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 … • N,N-dimethyltryptamine and the pineal gland: Separating fact from myth • The effect of N, N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide • Determination of N, N-dimethyltryptamine and β-carboline alkaloids in human plasma following oral administration of Ayahuasca
  • UW Psilocybin Pharmacokinetics Study • Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors • Psychopharmacology of Psilocybin in Cancer Patients • Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators • Psilocybin Cancer Anxiety Study • Effects of Dimethyltryptamine in Healthy Subjects • Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression


  • Microdelics • Super Funguy • Zamnesia • Spore Wellness • Mycology Now • Magic Mushrooms Dispensary • The Myco Grow • ShroomsDirect • Blue Goba • Psilo Supplements • Champignon Magique • Medicinal Mushroom Dispensary • Microdose Nature • Midwest Grow Kits • Quality Spores • North Spore • Chakra Openings • Cyber-Shrooms • ProviThor • DanceSafe • La Sociedad Psicodélica • MUD\WTR • Azarius • Magic Mushrooms Shop • Shroom Supply • Wholecelium • Avalon Magic Plants • Gorilla Mushroom Kits • Truffle Magic • Elephants • Dutch Growkits • Per Grow • Mushbox • Zativo • Exotic Psyche Pharmaceuticals


  • PRATI • California Institute of Integral Studies • King College London, Institute of Psychiatry, Psychology & Neuroscience • University of Madison-Wisconsin, School of Pharmacy • Maastricht University, Faculty of Psychology and Neuroscience • Johns Hopkins, Center for Psychedelic & Consciousness Research • St. Vincent's Hospital, Melbourne • Psychedelics Asia • Kosmicare • Psilopedia • Adventures Through The Mind • The Psychedelics Analyst • Remedium Project • Psychedelic Psychotherapy Forum • Drug Science • Mindspace • Naropa University • Heffter Research Institute • Psychedelics Today • Micro Mushroom Resource Centre • Gaia • JFK University • CIIS Center for Psychedelic Therapies and Research • School for Advanced Studies in the Social Sciences • Entheogenesis Australis • The Sanctuary Project • Harmonia • DanceSafe • RestPit • Drugs and Me • Check-in Free Mind • NoBox Philipines • Safe Shore - Hof Mivtahim • DÁT2 Psy Help • Keep Smiling • The Psychedelic Society of First Responders and Emergency Workers • Psychedelics and Philosophy • Psychedelic Grad • Evolver • PsychonautWiki • PEERS: Portland Entheogenic Exploration and Research Society • KRIYA Institute (Ketamine Research Institute) • Psychedelic Club • Students for Sensible Drug Policy (SSDP) • Chacruna • PsyCare UK, Welfare and Harm Reduction • Asociación Transpersonal Iberoamericana • ICEERS • Slovak psychedelic society - SAPAS • Awaken • EmmaSofia • Espolea • Alius Research Group • Psychedelic Society Lithuania • Sociedad Psiquedelica Mexico • The Psychedelic Society of the Netherlands • Psychedelics New Zealand • Palestinian Psychedelic Society • Polskie Towarzystwo Psychodeliczne • Lisbon Psychedelic Society • Portuguese Psychedelic Society Portuguese Psychedelic Society • The Psychedelic Society of Edinburgh • The Psychedelic Society of Slovenia • The Psychedelic Society of Madrid • La Sociedad Psicodélica • DanceWize • Herbs and Wonders • Psychedelic Society of Birmingham • The Psychedelic Society • Cambridge Psychedelic Society • Psychedelic Integration UK • The Maudsley Psychedelic Society • UCL Society for the Application of Psychedelics • The Psychedelic Society of Manchester • Solent Psychedelic Community • Psychedelics Courses • Neuly • Sanctus • Psilocybin Foundation • Psychedelic Medicine Association • Psychedelic Institute • Neuma Coaching • Shroomery • Integration Communications • Psychedelic Psychiatry • Psychedelic Warriors • Courage Quests • Imperial College London • Integrative Psychiatry Institute • Berkeley Center for the Science of Psychedelics (BCSP) • REBBLS • Andromeda Entertainment • Charisma on Command • Simba Health • University of Greenwich • Mental Health Professionals Network • MIND Foundation • Portland Psychedelic Society • MAPS Canada • University of Amsterdam, Psychology Research Institute • Zentralinstitut für Seelische Gesundheit • American College of Neuropsychopharmacology • Olson Lab • University of the Sciences • Intercollegiate Psychedelics Network • Psychedelic Pharmacists Association • Atitlantis • Forest Medicine Coaching • Micro-dosing for Healing • Frequency • Bloomers • OVID Health Systems • German Federal Ministry of Education and Research • Beyond Psychedelics • Bmore Psychedelic Society • Catalyst Calgary • Decriminalize Nature • Decriminalize Nature Canada • Edelic Center for Ethnobotanical Services • Erie Vision • The Newly Institute • Psychedelic Social Justice Collective • Healing Advocacy Fund • MAPS • Society for Psychedelic Outreach Reform and Education (SPORE) • Aphrodite Health
  • Sr Director, Head of Commercialization and Patient Access • Executive Director


  • Meet Delic • The Green Light • Microdose • McKenna Academy • Mind Medicine Australia • 920 Coalition • Psychedelic Psychotherapy Forum • PsyTech (events) • Catharsis on the Mall • Exploring Psychedelics • Horizons • Reform Conference • Women's Visionary Congress • Breaking Convention • Entheogenesis Australis • Safe Shore - Hof Mivtahim • Psychedelic Seminars • PEERS: Portland Entheogenic Exploration and Research Society • DanceWize • Swedish Institute for Psychedelic Science • Psychedelic Society Switzerland • Dandelion • Entheo Generation • REBBLS • Mental Health Professionals Network • CNS Summit • Bloomers • Psychedelic Social Justice Collective


  • Jazz Pharmaceuticals
  • Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome • Gamma hydroxybutyric acid (GHB) intoxication • Gamma‐hydroxybutyric acid in the treatment of alcohol dependence: a double‐blind study • Gamma‐hydroxybutyric acid: an emerging recreational drug • Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans • Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers • Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal • Abuse and therapeutic potential of gamma-hydroxybutyric acid • Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence • Gamma-hydroxybutyric acid as hypnotic. Clinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man. • Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome
  • Characterization of the Prosocial and Prosexual Effects of GHB • Personality Disorders and Substance Use Disorders in a Sexual Context in the Man Having Sex With Other Men Population • Xyrem and Brain Dopamine in Narcolepsy • Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor • Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD) • Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease • GHB Poisoning and Poisoning Induced by Others • Physiological, Behavioral and Subjective Effects of Drugs (GHB) • Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome • Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate • Sodium Oxybate in Schizophrenia With Insomnia • Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes • The Effect of Sodium Oxybate on Sleep Architecture • Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia • A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics • Sodium Oxybate in Patients With Chronic Fatigue Syndrome. • Sodium Oxybate in Idiopathic Hypersomnia • Enhancing Slow Wave Sleep With Sodium Oxybate • Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome • Sodium Oxybate in Patients With Episodic and Chronic Cluster Headache • Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients • Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response • Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO) • Xyrem(Sodium Oxybate) and Ambien(Zolpidem Tartrate) in the Treatment of Chronic Insomnia. • SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE) • Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy • Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy • Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia • Pharmacokinetics Study: Determination of Naproxcinod and Its Metabolites After Oral Administration in Male • Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia • Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy • Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia. • Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor • Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients • A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia. • Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription • Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients • Sodium Oxybate in the Treatment of Binge Eating Disorder • Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction • An Open Label Study of FT218 in Subjects With Narcolepsy • Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV) • Impact of Gamma-OH on Sleep in ICU Patients • A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy • Memory Consolidation in Pharmacologically Enhanced Naps • Towards a Post-exposition Pharmacological Prophylaxis for Post-traumatic Stress Disorder


  • Ceiba • Iboga Quest • Iboga Soul • Clear Sky Recovery • Entheogenesis Australis
  • An Observational Pre-post Study Evaluating the Safety of Tabernanthe Iboga Exposure


  • Universal Ibogaine • DemeRx • ATAI Life Sciences • Ceiba • Iboga Quest • Iboga Soul • Inner Realms Center • Clear Sky Recovery • Headland • Mera Life Sciences • Delix Therapeutics • Mr. Psychedelic Law • Entheogenesis Australis • Society for Psychedelic Outreach Reform and Education (SPORE)
  • Ibogaine: a review • The ibogaine medical subculture • Treatment of acute opioid withdrawal with ibogaine • Effects and aftereffects of ibogaine on morphine self-administration in rats • Inhibitory effects of ibogaine on cocaine self-administration in rats • Mechanisms of Antiaddictive Actions of Ibogainea • Ibogaine possesses a selective affinity for σ2 receptors • Medication Development of Ibogaine as a Pharmacotherapy for Drug Dependencea • Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures • Ibogaine neurotoxicity: a re-evaluation • Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine • Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies • Radioligand-binding study of noribogaine, a likely metabolite of ibogaine • Ibogaine antagonizes cocaine-induced locomotor stimulation in mice • A preliminary investigation of ibogaine: case reports and recommendations for further study • Ibogaine in the treatment of heroin withdrawal • Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor • Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline • Ibogaine-like effects of noribogaine in rats • Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats • Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats. • Ibogaine and its congeners are σ2 receptor-selective ligands with moderate affinity • NMDA antagonist properties of the putative antiaddictive drug, ibogaine. • Ibogaine induces glial activation in parasagittal zones of the cerebellum • Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin • Ibogaine reduces preference for cocaine consumption in C57BL/6By mice • Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration • Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study • Ibogaine in the treatment of substance dependence • Fatalities temporally associated with the ingestion of ibogaine • Pharmacodynamics and therapeutic applications of iboga and ibogaine • Serotonin transporter–ibogaine complexes illuminate mechanisms of inhibition and transport • Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption • Chemical Transformations of Ibogaine • The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity • The Alkaloids of Tabernanthe iboga. Part IV.1 The Structures of Ibogamine, Ibogaine, Tabernanthine and Voacangine • Use of ibogaine for treating neuropathic pain • Ibogaine therapy: A'Vast, uncontrolled experiment' • The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters • Sex differences in ibogaine antagonism of morphine-induced locomotor activity and in ibogaine brain levels and metabolism • Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats • Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes • 18‐Methoxycoronaridine (18‐MC) and Ibogaine: Comparison of antiaddictive efficacy, toxicity, and mechanisms of action • Ibogaine and the dopaminergic response to nicotine • Ibogaine: a potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors • Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats • The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine • The putative anti-addictive drug ibogaine is a competitive inhibitor of MK-801 binding to the NMDA receptor complex • Excitotoxic insult due to ibogaine leads to delayed induction of neuronal NOS in Purkinje cells. • Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter • How toxic is ibogaine? • Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review • Ibogaine fails to reduce naloxone-precipitated withdrawal in the morphine-dependent rat • Interaction of ibogaine and d-amphetamine: in vivo microdialysis and motor behavior in rats • Potentiation action of ibogaine (bogadin TM) on morphine analgesia • Treating drug dependence with the aid of ibogaine: A retrospective study • The structure of ibogaine • Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors • Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine • Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine • Effects of ibogaine on naloxone‐precipitated withdrawal in morphine‐dependent mice • Ibogaine block of the NMDA receptor: in vitro and in vivo studies • Long-QT syndrome induced by the antiaddiction drug ibogaine • Interactions between ibogaine and cocaine in rats: in vivo microdialysis and motor behavior. • Neurochemical and behavioural interactions between ibogaine and nicotine in the rat • In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats • Unique and potent effects of acute ibogaine on zebrafish: the developing utility of novel aquatic models for hallucinogenic drug research • Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex • Iboga Alkaloids. II.1 the Structures of Ibogaine, Ibogamine and Tabernanthine • Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca • Comparison of the behavioral effects of ibogaine from three sources: mediation of discriminative activity • Effects of ibogaine on responding maintained by food, cocaine and heroin reinforcement in rats • The use of ibogaine in the treatment of addictions • High affinity ibogaine binding to a mu opioid agonist site • Prior morphine exposure enhances ibogaine antagonism of morphine-induced locomotor stimulation • Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener • Ibogaine-associated ventricular tachyarrhythmias • Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine • The anti-addiction drug ibogaine and the heart: a delicate relation • Life-threatening complications of ibogaine: three case reports • Ibogaine modulates cocaine responses which are altered due to environmental habituation: in vivo microvoltammetric and behavioral studies • Acute toxicity of ibogaine and noribogaine • Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study • Ibogaine selectively inhibits nicotinic receptor-mediated catecholamine release • Ibogaine affects brain energy metabolism • Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-D-aspartate receptors • Ibogaine reduces amphetamine-induced locomotor stimulation in C57BL/6By mice, but stimulates locomotor activity in rats • Facilitation of memory retrieval by the “anti-addictive” alkaloid, ibogaine • Cardiac arrest after ibogaine ingestion • Ibogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors • Bioactive tricyclic ibogaine analogs • DARK classics in chemical neuroscience: Ibogaine • Anti‐addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk • Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction • A contemporary history of ibogaine in the United States and Europe • Autoregulation of glial cell line‐derived neurotrophic factor expression: implications for the long‐lasting actions of the anti‐addiction drug, Ibogaine • Differential effects of ibogaine pretreatment on brain levels of morphine and (+)-amphetamine • A dose-response study of ibogaine-induced neuropathology in the rat cerebellum • Evidence that ibogaine releases dopamine from the cytoplasmic pool in isolated mouse striatum • Ibogaine, a putatively anti-addictive alkaloid • Stimulus effects of ibogaine in rats trained with yohimbine, DOM, or LSD • Case studies of ibogaine treatment: implications for patient management strategies • Evidence for roles of κ-opioid and NMDA receptors in the mechanism of action of ibogaine • Identification and Quantitation of Ibogaine and an o-Demethylated Metabolite in Brain and Biological Fluids Using Gas Chromatography-Mass Spectrometry • Ibogaine related sudden death: a case report • Long-lasting ibogaine protection against NMDA-induced convulsions in mice • Distribution of Ibogaine and Noribogaine in a Man Following a Poisoning Involving Root Bark of the Tabernanthe iboga Shrub • Modulation of morphine-induced antinociception by ibogaine and noribogaine • Local effects of ibogaine on extracellular levels of dopamine and its metabolites in nucleus accumbens and striatum: interactions with d-amphetamine • Identification and quantification of the indole alkaloid ibogaine in biological samples by gas chromatography-mass spectrometry • Total synthesis of ibogaine, epiibogaine and their analogues • Neuroendocrine and neurochemical effects of acute ibogaine administration: a time course evaluation • Effect of ibogaine on serotonergic and dopaminergic interactions in striatum from mice and rats • Noribogaine (12‐hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine • Behavioral and biochemical evidence for a nonessential 5-HT2A component of the ibogaine-induced discriminative stimulus • Effects of ibogaine, and cocaine and morphine after ibogaine, on ventral tegmental dopamine neurons • Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain • Noribogaine, but not 18‐MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self‐administration • Ibogaine and the inhibition of acetylcholinesterase • Ibogaine acts at the nicotinic acetylcholine receptor to inhibit catecholamine release • The need for ibogaine in drug and alcohol addiction treatment • Effects of chronic ibogaine treatment on cerebellar Purkinje cells in the rat • Ibogaine effects on sweet preference and amphetamine induced locomotion: implications for drug addiction • Determination of ibogaine in plasma by gas chromatography-chemical ionization mass spectrometry • Neuropharmacological characterization of local ibogaine effects on dopamine release • Effect of ibogaine on cocaine-induced efflux of dopamine and serotonin from mouse striatum • Effects of ibogaine on sensory-motor function, activity, and spatial learning in rats • Ibogaine and addiction in the animal model, a systematic review and meta-analysis • Ibogaine and noribogaine: comparing parent compound to metabolite • Growing menace of ibogaine toxicity • Modified Ibogaine Fragments: Synthesis and Preliminary Pharmacological Characterization of 3-Ethyl-5-phenyl-1,2,3,4,5,6-hexahydroazepino … • Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: a study to assess the drug's cardiac ion channel profile • Differential effects of ibogaine on behavioural and dopamine sensitization to cocaine • Ibogaine reduces organ colonization in murine systemic and gastrointestinal Candida albicans infections • Ibogaine as a glutamate antagonist: relevance to its putative antiaddictive properties • Ibogaine analogues. Synthesis and preliminary pharmacological evaluation of 7-heteroaryl-2-azabicyclo oct-7-enes • Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine • The identification of ibogaine in biological material • Ibogaine alters synaptosomal and glial glutamate release and uptake • Ibogaine: Proceedings from the First International Conference • Abbreviated ibogaine congeners. Synthesis and reactions of tropan-3-yl-2-and-3-indoles. Investigation of an unusual isomerization of 2-substituted indoles using … • Responses of the extrapyramidal and limbic substance P systems to ibogaine and cocaine treatments • Use of ibogaine in reducing excitotoxic brain damage • Ibogaine attenuates morphine-induced conditioned place preference. • Prior morphine exposure enhances ibogaine antagonism of morphine-induced dopamine release in rats • Interaction of ibogaine with human α3β4-nicotinic acetylcholine receptors in different conformational states • Ibogaine signals addiction genes and methamphetamine alteration of long‐term potentiation • Drug discrimination studies with ibogaine • Anxiogenic action of ibogaine • Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder • Ibogaine and noribogaine potentiate the inhibition of adenylyl cyclase activity by opioid and 5-HT receptors • The effect of ibogaine on κ-opioid-and 5-HT3-induced changes in stimulation-evoked dopamine release in vitro from striatum of C57BL/6BY mice • Ibogaine for treating drug dependence. What is a safe dose? • Effect of Ibogaine on the Various Sites of the NMDA Receptor Complex and Sigma Binding Sites in Rat Braina • The effects of ibogaine on dopamine and serotonin transport in rat brain synaptosomes • Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine • Determination of ibogaine and 12-hydroxy-ibogamine in plasma by gas chromatography-positive ion chemical ionization-mass spectrometry • Effects of LSD 25, BOL 148, bufotenine, mescaline and ibogaine on the potentiation of hexobarbital hypnosis produced by serotonin and reserpine • Cytochrome P450 and O-methyltransferase catalyze the final steps in the biosynthesis of the anti-addictive alkaloid ibogaine from Tabernanthe iboga • Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes • Characterization of the discriminable stimulus produced by 2‐BFI: effects of imidazoline I2‐site ligands, MAOIs, β‐carbolines, agmatine and ibogaine • Characterization of multiple sites of action of ibogaine • Differential responses by neurotensin systems in extrapyramidal and limbic structures to ibogaine and cocaine • Effects of ibogaine on the development of tolerance to antinociceptive action of μ-, δ-and κ-opioid receptor agonists in mice • Ibogaine enhances the expression of locomotor sensitization in rats chronically treated with cocaine • Alteration in electroencephalogram and monoamine concentrations in rat brain following ibogaine treatment • Ibogaine therapy for substance abuse disorders • Comparative neurobiological effects of ibogaine and MK-801 in rats • Effects of ibogaine and noribogaine on the antinociceptive action of μ-, δ-and κ-opioid receptor agonists in mice • The effect of ibogaine on sigma-and NMDA-receptor-mediated release of dopamine • Ibogaine acute administration in rats promotes wakefulness, long-lasting REM sleep suppression, and a distinctive motor profile • The effects of sigma, PCP, and opiate receptor ligands in rats trained with ibogaine as a discriminative stimulus • Ibogaine interferes with motivational and somatic effects of naloxone-precipitated withdrawal from acutely administered morphine • Tabernanthine, ibogaine containing analgesic compositions • Determination of ibogaine and noribogaine in biological fluids and hair by LC–MS/MS after Tabernanthe iboga abuse: Iboga alkaloids distribution in a drowning death … • A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 β-carbolines, ibogaine, and yohimbine in human urine and plasma … • Derivatives of ibogamine, ibogaine and ibogaline lactams • Disposition of ibogaine in the rat • Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice • Pharmacokinetic characterization of the indole alkaloid ibogaine in rats • Effects of ibogaine and noribogaine on phosphoinositide hydrolysis • Treating drug dependence with the aid of ibogaine: A qualitative study • Ibogaine interferes with the establishment of amphetamine place preference learning. • Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers • Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys • In Vivo Ibogaine Blockade and In Vitro PKC Action of Cocainea • Effects of ibogaine on performance in the 8-arm radial maze • From the roots up: ibogaine and addict self-help • Ibogaine blocked methamphetamine-induced hyperthermia and induction of heat shock protein in mice • Ibogaine fails to interrupt the expression of a previously established one-trial morphine place preference. • Differential effects of ibogaine on local cerebral glucose utilization in drug-naive and morphine-dependent rats • Effects of low dose ibogaine on subjective mood state and psychological performance • Mania following use of ibogaine: A case series • Liquid chromatography–electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood: Application to a poisoning … • Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review • Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19 • Acute ibogaine injection induces expression of the immediate early genes, egr-1 and c-fos, in mouse brain • Internet-purchased ibogaine toxicity confirmed with serum, urine, and product content levels • Remission of severe opioid Use disorder with ibogaine: a case report • Ibogaine neurotoxicity assessment: electrophysiological, neurochemical, and neurohistological methods • Modulation of the effects of rewarding drugs by ibogaine • Manual for ibogaine therapy: screening, safety, monitoring & aftercare • Morphing of Ibogaine: A Successful Attempt into the Search for Sigma-2 Receptor Ligands • The antiaddictive effects of ibogaine: A systematic literature review of human studies • Acute and chronic administration of ibogaine to the rat results in astrogliosis that is not confined to the cerebellar vermis • The effects of noribogaine and harmaline in rats trained with ibogaine as a discriminative stimulus • Cholecystokinin octapeptide (CCK-8), ceruletide and analogues of ceruletide: Effects on tremors induced by oxotremorine, harmine and ibogaine a comparison with … • Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short-and long-term outcomes and current psychological functioning • A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment • Metabolic plasticity and the energy economizing effect of ibogaine, the principal alkaloid of Tabernanthe iboga • Neurochemical and neuroendocrine effects of ibogaine in rats: Comparison to MK‐801 • Ibogaine-associated cardiac arrest and death: case report and review of the literature • Fatal Case of a 27‐Year‐Old Male After Taking Iboga in Withdrawal Treatment: GC‐MS/MS Determination of Ibogaine and Ibogamine in Iboga Roots and Postmortem … • Ibogaine and a total alkaloidal extract of Voacanga africana modulate neuronal excitability and synaptic transmission in the rat parabrachial nucleus in vitro • Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine • Ibogaine therapy for addiction: Consumer views from online fora • The mystery of ibogaine: can an African psychedelic cure addiction? • Ibogaine-associated psychosis in schizophrenia: a case report • Administration of a non-NMDA antagonist, GYKI 52466, increases excitotoxic Purkinje cell degeneration caused by ibogaine • A mixed-method analysis of persisting effects associated with positive outcomes following ibogaine detoxification • Comparison of the hallucinogenic indole alkaloids ibogaine and harmaline for potential immunomodulatory activity • Ibogaine: A novel anti-addictive compound • Pretreatment with the putative anti-addictive drug, ibogaine, increases the potency of cocaine to elicit locomotor responding: a study with acute and chronic cocaine … • Quantification of Anti‐Addictive Alkaloids Ibogaine and Voacangine in In Vivo‐ and In Vitro‐Grown Plants of Two Mexican Tabernaemontana Species • Ibogaine pretreatment dramatically enhances the dynorphin response to cocaine • Structure of ibogaine • Further investigations of the serotonergic properties of the ibogaine-induced discriminative stimulus. • Metallation/reduction as a new approach to tritium labeling. The synthesis of ibogaine • Ibogaine in the treatment of narcotic withdrawal • The development and expression of locomotor sensitization to nicotine in the presence of ibogaine • 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. • Ibogaine in the 21st century: boosters, tuneups and maintenance • The anti-addictive drug ibogaine modulates voltage-gated ion channels and may trigger cardiac arrhythmias • Quantitation of ibogaine and 12-hydroxyibogamine in human plasma by liquid chromatography with fluorimetric detection • A preliminary report on the safety and pharmacokinetics of ibogaine • Sur l'ibogaine • A Single Administration of the Atypical Psychedelic Ibogaine or its Metabolite Noribogaine Induces an Antidepressant-like Effect in Rats • Examination of the phenomenology of the ibogaine treatment experience: Role of altered states of consciousness and psychedelic experiences • Ibogaine administration modifies GDNF and BDNF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits • Ibogaine as a treatment for substance misuse: potential benefits and practical dangers • Understanding the healing potential of ibogaine through a comparative and interpretive phenomenology of the visionary experience • Methods and compositions for reducing tolerance to opioid analgesics using ibogaine and derivatives thereof • Detection and Identification of Ibogaine and Heroin • The effects of β-carbolines in rats trained with ibogaine as a discriminative stimulus • Ibogaine-structure, influence on human body, clinical relevance • Ibogaine labeling with 99mTc-tricarbonyl: synthesis and transport at the mouse blood–brain barrier • Detoxification from methadone using low, repeated, and increasing doses of ibogaine: A case report • Breaking the cycle of opioid use disorder with ibogaine • Methods for acute and long-term treatment of substance abuse using ibogaine • Induction of energy metabolism related enzymes in yeast Saccharomyces cerevisiae exposed to ibogaine is adaptation to acute decrease in ATP energy pool • A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder • Solution-phase parallel synthesis of N, 6-disubstituted isoquinuclidines as ibogaine analogs • “Herbal seizures”–atypical symptoms after ibogaine intoxication: a case report • Structure–activity relationship of ibogaine analogs interacting with nicotinic acetylcholine receptors in different conformational states • Liquid chromatography-electrospray mass spectrometry determination of ibogaine and 12-hydroxy-ibogamine in human urine • A phenomenological investigation into the lived experience of ibogaine and its potential to treat opioid use disorders • Extraction and Conversion Studies of the Antiaddictive Alkaloids Coronaridine, Ibogamine, Voacangine, and Ibogaine from Two Mexican Tabernaemontana Species … • Ex vivo effects of ibogaine on the activity of antioxidative enzymes in human erythrocytes • Investigation into pharmacokinetic properties of active alkaloid ibogaine and its metabolite noribogaine • Ibogaine therapy in the treatment of opiate dependency • Ibogaine interferes with the establishment of conditioned taste avoidance produced by morphine and lithium • Neuropharmacological studies on ibogaine, an indole alkaloid with central-stimulant properties. • Anti-addiction drug ibogaine prolongs the action potential in human induced pluripotent stem cell-derived cardiomyocytes • Cardiac arrest after ibogaine intoxication • The effects of ibogaine on uterine smooth muscle contractions: relation to the activity of antioxidant enzymes • Ibogaine and Noribogaine: Structural Analysis and Stability Studies. Use of LC‐MS to Determine Alkaloid Contents of the Root Bark of Tabernanthe Iboga • Ibogaine produces neurodegeneration in rat, but not mouse, cerebellum: Neurohistological biomarkers of Purkinje cell loss • Assessment of neurotoxicity from potential medications for drug abuse: ibogaine testing and brain imaging • Ibogaine--the substance for treatment of toxicomania. Neurochemical and pharmacological action • The Ibogaine Experience: A Qualitative Study on the Acute Subjective Effects of Ibogaine • Ibogaine and the treatment of opiate addiction • Combating substance abuse with ibogaine: Pre-and posttreatment recommendations and an example of successive model fitting analyses • A new approach to tritium labelling; the synthesis of ibogaine • Application of electrophysiological method to study interactions between ibogaine and cocaine • Ibogaine II: down memory lane; does one trip equal 30 years on a therapist's couch? • Effect of ibogaine on the development of tolerance to the analgesic effect of morphine. • Pharmacological comparison of the effect of ibogaine and 18‐methoxycoronaridine on isolated smooth muscle from the rat and guinea‐pig • Life after ibogaine • Ibogaine: therapeutic miracle • A COMPARATIVE STUDY ON THE TOXICITY OF IBOGAINE AND SEROTONIN. • Ibogaine Treatment in Aotearoa/New Zealand: Developing a unique model of practice • Cardiac arrest after ibogaine ingestion • Hallucinogen persisting perception disorder after ibogaine treatment for opioid dependence • Ibogaine Consumption With Seizure-Like Episodes, QTc-Prolongation, and Captured Cardiac Dysrhythmias • Methods and compositions for treating depression using ibogaine • An analytical study of iboga alkaloids contained in Tabernanthe iboga-derived products offered by ibogaine treatment providers • Ibogaine in acute opioid withdrawal: An open label case series • Low dose administration of ibogaine for treating nicotine addiction and preventing relapse of nicotine use • Ibogaine offers an alternative approach for treating opiate addiction • NOS and fos in Rat and Mouse Brain Regions: Possible Relation to Ibogaine‐Induced Purkinje Cell Loss • Analysis of the cardiovascular action of ibogaine hydrochloride. • Anesthesia for opiate detoxification and the ibogaine controversy • Development of novel medications for drug addiction: The legacy of an African shrub • Observations on treatment with ibogaine. • Changes in gene expression and signal transduction following ibogaine treatment • The anti-addiction drug ibogaine inhibits cardiac ion channels: a study to assess the drug's proarrhythmic potential • Novel treatment of opioid use disorder using ibogaine and iboga in two adults • … effect of alkaloids from Tabernanthe iboga H. Bn. on the response of isolated organs to catecholamines and the possible role of calcium exchange. Case of Ibogaine • Methods for acute and long-term treatment of alcohol dependence using ibogaine • The visionary cure of the addiction war? Ibogaine: social context, subcultural identity, and implications for drug policy • Biosynthesis of the Iboga alkaloids: the incorporation of tryptophan-3-C14 into ibogaine • lbogaine Alters Cocaine-Induced Biogenic Amine and Psychostimulant Dysfunction but not GBR-12935 Binding to the Dopamine Transporter Protein • N-(Hydroxymethyl) ibogaine • Gamma band alterations and REM-like traits underpin the acute effect of the atypical psychedelic ibogaine • Interactions between ibogaine and morphine: Neuropharmacological and pharmacokinetic determinants. • Detection de l'ibogaine dans les liquides organiques • … of Ibogaine and Ibogaine-Related Alkaloids. in The Alkaloids. Chemistry and Biology Pharmacology of Ibogaine and Ibogaine-Related Alkaloids. in The … • N-(Hydroxymethyl) ibogaine • Gamma band alterations and REM-like traits underpin the acute effect of the atypical psychedelic ibogaine • Interactions between ibogaine and morphine: Neuropharmacological and pharmacokinetic determinants. • Detection de l'ibogaine dans les liquides organiques • … of Ibogaine and Ibogaine-Related Alkaloids. in The Alkaloids. Chemistry and Biology Pharmacology of Ibogaine and Ibogaine-Related Alkaloids. in The … • N-(Hydroxymethyl) ibogaine • Gamma band alterations and REM-like traits underpin the acute effect of the atypical psychedelic ibogaine • Interactions between ibogaine and morphine: Neuropharmacological and pharmacokinetic determinants. • Detection de l'ibogaine dans les liquides organiques • N-(Hydroxymethyl) ibogaine • Gamma band alterations and REM-like traits underpin the acute effect of the atypical psychedelic ibogaine • Interactions between ibogaine and morphine: Neuropharmacological and pharmacokinetic determinants. • Gamma band alterations and REM-like traits underpin the acute effect of the atypical psychedelic ibogaine • Interactions between ibogaine and morphine: Neuropharmacological and pharmacokinetic determinants. • Gamma band alterations and REM-like traits underpin the acute effect of the atypical psychedelic ibogaine • Interactions between ibogaine and morphine: Neuropharmacological and pharmacokinetic determinants. • Methods for the detection and determination of ibogaine in biological materials. • A case of QT prolongation and torsades de pointes caused by ibogaine toxicity • Anti-addiction drug ibogaine on trial • Ibogaine Toxicity In A Case Of Good Intentions • IBOGAINE MAY HELP DRUG ADDICTS LIVE THE 'NEVER AGAIN' • Ibogaine Binds Human Serotonin Transporter in Multiple Functional States • QTC prolongation progressing to torsade de pointes secondary to ibogaine ingestion • Experiences of opioid detoxification using ibogaine in various treatment settings: Exploring ibogaine users' motivations, understanding of risks, and effects of ibogaine … • An approach to the synthesis of ibogaine • Psychedelics and quasi-psychedelics in the light of contemporary research: Medical cannabis, MDMA, salvinorin A, ibogaine and ayahuasca • Effects of ibogaine per os application on redox homeostasis in rat liver and erythrocytes • A tropane-based ibogaine analog rescues folding-deficient SERT and DAT • Potential use of medicinal plants in the treatment of alcoholism • Ibogaine modifies GDNF, BDNF and NGF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits • Thin Layer Chromatography of Lysergic Acid Diethylamide (LSD), N, N Dimethyl Tryptamine (DMT), Methylene Dioxyphenyl Isopropylamine (STP), and Ibogaine • Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake • Serotonin transporter–ibogaine complexes illuminate mechanisms of inhibition and transport • Gas chromatographic determination of iboga ine in biological fluids • Ibogaine • Ibogaine overdose • Ibogaine overdose • Clinical and Demographic Profile Analysis of Patients Receiving Ibogaine Treatment for Substance Use Disorders in Mexico • Ibogaine overdose • Ibogaine abuse • Ibogaine: History, Pharmacology, Spirituality, & Clinical Data • Ibogaine “ • The Phenomenology of Ibogaine-assisted Addiction Therapy: Understanding the Role of the Visionary Experience in Healing
  • Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification • Ibogaine in the Treatment of Alcoholism: a Randomized, Double-blind, Placebo-controlled, Escalating-dose, Phase 2 Trial


  • Psychedelic Experience • Entheon Nation • Kahpi • Plant Medicine • Mushstocks • Set and Setting • The Journal of Psychedelic Psychiatry • Medicine Hunter • High Existence • Aya Visionary • Trip Therapie • The Psychedelic Anthology • A Whole New High • Alien Insect • Trip Safe • McKenna Academy • Guided Tripping • Modern Psychedelics • Psychedelics Asia • Kosmicare • MOOF • Psilopedia • Adventures Through The Mind • Alan Aldous • Psyched • Psychedelic Spotlight • Psychedelic Frontier • The Psychedelics Analyst • Psyched Substance • It's Psychedelic Baby Magazine • The Psychedelic Investor • Drugs Data • Isomer Design • TruHavn • Shroom Stocks • Shroom Street • VICE • European Monitoring Centre for Drugs and Drug Addiction • Mind Medicine Australia • Remedium Project • Neurosight • Psychedelic.Direct • The Natural Microdosing Society • PsyIndex • Center for the Neuroscience of Psychedelics • Drug Science • Pacific Neuroscience Institute • Psychedelics Today • Micro Mushroom Resource Centre • Gaia • PRØHBTD • Opportune • DanceSafe • Psychedelics Courses • Goop • Behold Retreats • Psychedelic Stockwatch • Neuly • RiverStyx Foundation • Prohibition Partners • Mindstrong • Dandelion • Sanctus • Business Trip • Psychedelic News Wire • Psilocybin Foundation • Psychedelic Medicine Association • Psychedelic Institute • Shroomery • WILD 5 Wellness • Spirit Pharmacist • Psychedelics Daily • Maps of the Mind • The Oak Tree Review • DMT Times • The Daily Psychedelic Video • Psychedelic Traveler • Ketamine Directory • Truffle Report • Puff Digital • MyDelica • PuraPhy • Enter Here • Psynautics • How To Use Psychedelics • Mr. Psychedelic Law • Psychedelic Social Justice Collective • Healing Advocacy Fund • Society for Psychedelic Outreach Reform and Education (SPORE)
  • Freelance Writer • Research Associate III - Effects of psychedelics on human cortical cell types